AptarGroup, Inc. (NYSE:ATR) announced on March 17, 2026 that Gael Touya, a long‑time executive with more than 30 years at the company, will become President and Chief Executive Officer effective September 1, 2026. Touya most recently served as Aptar Pharma President and will succeed Stephan B. Tanda, who has led the company since 2017 and will retire from the Board by the end of 2026.
Touya’s appointment follows a rigorous succession‑planning process that evaluated internal and external candidates. The Board unanimously selected him, citing his deep experience across Aptar’s Pharma, Beauty, and Closures segments and his track record of expanding the company’s drug‑delivery capabilities. Under Touya’s leadership, the Pharma segment has grown 82% in topline sales since September 2018, a growth rate that far outpaces the company’s overall revenue expansion.
Tanda’s tenure has been marked by disciplined capital allocation and margin improvement. Adjusted EBITDA margins expanded from roughly 19% in 2017 to about 22% in 2025, and adjusted EPS grew 67% during his leadership. The company also maintained a 32nd consecutive year of increasing dividends, returning $486 million to shareholders in 2025.
In its most recent quarterly report, AptarGroup posted Q4 2025 revenue of $963 million, up 14% year‑over‑year, and adjusted EPS of $1.25, beating consensus estimates of $1.23 by $0.02. Reported EPS of $1.13 fell 24% from the prior year, reflecting higher production costs in the beauty enclosure segment and a shift in product mix that reduced demand for emergency‑medicine products. The adjusted EBITDA margin contracted to about 20% from 23% in the prior year, largely due to those cost pressures.
Segment‑level performance showed Pharma sales rising 10% (core sales up 4%), Beauty sales increasing 24% (core sales up 10%), and Closures sales growing 5% (core sales up 1%). The strong growth in Pharma and Beauty offsets margin compression in the Closures segment, where operational disruptions contributed to a modest sales increase.
Management highlighted the continuity and confidence in the transition. Chairperson Candace Matthews said, "Following a thorough succession planning and selection process that considered both internal and external candidates, the Board unanimously concluded that Gael was the best choice to lead Aptar into its next chapter. The Board has full confidence in his vision for the Company." Touya added, "I am honored to step into this role. Aptar has been my professional home for more than 30 years, and I am energized by the opportunity to help shape the Company’s future alongside our global teams." Tanda noted, "All three segments delivered core sales growth, driving a total increase of 5% in the fourth quarter and underscoring our strong market positions and the benefits of our innovation‑led portfolio. Our Pharma segment’s growth was driven by strong demand for our elastomeric components, continued demand for our systemic nasal drug delivery technologies and the return to growth for our consumer healthcare division. Our Beauty segment delivered double‑digit growth, driven by healthy demand for our dispensing technologies across all end markets, and our Closures segment had strong product volume growth. A combination of product mix and some higher than expected production costs reduced the impact of our strong top line results on our overall profitability in the quarter. We remain confident in our ability to drive performance and to continue creating value for shareholders."
The transition underscores Aptar’s focus on sustaining its competitive moat in regulated drug delivery while continuing to invest in innovation, ESG leadership, and disciplined capital allocation. With Touya’s deep expertise in pharma and a proven record of growth, the company is positioned to build on its momentum and navigate the next phase of expansion.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.